Endothelial dysfunction, inflammation and statins: New evidences;Disfunción endotelial, inflamación y estatinas: Nuevas evidencias

Revista Espanola de Cardiologia

Volumn 57, Issue 10, 2004, Pages 903-905

  Tuñón, José ^a   Egido, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; DIPYRIDAMOLE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 6; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAVASTATIN;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; EDITORIAL; ENZYME SYNTHESIS; EVIDENCE BASED MEDICINE; FUNCTIONAL ASSESSMENT; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; NON INVASIVE MEASUREMENT; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM;

EID: 8344275165     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13066448     Document Type: Editorial

References (15)

1. Iraculis E, Cequier A, Sabate M, Pinto X, Antoni Gómez-Hospital J, Mauri J, et al. Improvement of endothelial function in patients with hypercholesterolemia and normal coronary arteries with lipid-lowering therapy. Rev Esp Cardiol 2001;54:685-92.
2. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
3. Hernández-Perera O, Pérez-Sala D, Navarro-Antolín J, Sánchez-Pacuala R, Hernández G, Díaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-9.
4. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001;103:113-8.
5. Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Pérez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;32:2057-64.
6. Herández-Presa MA, Martín-Ventura JL, Ortego M, Gómez-Hernández A, Tuñón J, Herná ndez-Vargas P, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002;160:49-58.
7. Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Díaz C, Herández G, et al. Atorvastatin reduces NF-κ B activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999;147:253-61.
8. Hernández-Presa MA, Ortego M, Tuñón J, Mas S, Martín-Ventura JL, Blanco-Colio LM, et al. Simvastatin reduces inflammation in peripheral mononuclear cells and in rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 2003;57:168-77.
9. Tomás JP, Moya JL, Campuzano R, Barrios V, Megías A, Ruiz S, et al. Determinación no invasiva del efecto de atorvastatina en la microvasculatura coronaria y la función endotelial periférica de pacientes dislipémicos. Rev Esp Cardiol 2004;57:909-15.
10. Smilde TJ, Van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81.
11. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80.
12. Fujimoto K, Hozumi T, Watanabe H, Shimada K, Takeuchi M, Sakanoue Y, et al. Effect of fluvastatin therapy on coronary flow reserve in patients with hypercholesterolemia. Am J Cardiol 2004;93:1419-21.
13. Gonzálvez M, Ruiz Ros JA, Pérez-Paredes M, Lozano ML, Jiménez DM, Martínez-Corbalán F, et al. Efecto de la administración precoz de pravastatina en los valores de proteína C reactiva y de interleucina 6 en la fase aguda del infarto de miocardio con elevación del segmento ST. Rev Esp Cardiol 2004;57:916-23.
14. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560-6.
15. Blanco-Colio LM, Tuñón J, Martin-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003;63:12-23.